Experienced in Sturge-Weber Syndrome

Dr. Ana M. Molina

Hematology Oncology | Oncology
Weill Medical College Of Cornell
525 E 68th St, 
New York, NY 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Experienced in Sturge-Weber Syndrome
Weill Medical College Of Cornell
525 E 68th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ana Molina is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Molina and is rated as an Experienced provider by MediFind in the treatment of Sturge-Weber Syndrome. Her top areas of expertise are Renal Cell Carcinoma (RCC), Prostate Cancer, Chromophobe Renal Cell Carcinoma, Tissue Biopsy, and Nephrectomy.

Her clinical research consists of co-authoring 72 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in NY
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

WEILL MEDICAL COLLEGE OF CORNELL
525 E 68th St, New York, NY 10021

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)
Enrollment Status: Recruiting
Publish Date: June 15, 2025
Intervention Type: Other, Procedure, Drug, Radiation
Study Drug: Cabozantinib S-malate
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: June 12, 2025
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
A Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Enrollment Status: Active_not_recruiting
Publish Date: May 23, 2025
Intervention Type: Drug
Study Drugs: Apalutamide, Abiraterone, Docetaxel, Prednisone
Study Phase: Phase 1
ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study
ARN-509+Abiraterone Acetate+Leuprolide With Stereotactic, Ultra-Hypofractionated Radiation (AASUR) in Very High Risk Prostate Cancer: A Single Arm, Phase II Study
Enrollment Status: Active_not_recruiting
Publish Date: May 20, 2025
Intervention Type: Drug, Radiation
Study Drugs: ARN-509, Abiraterone, Leuprolide
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: April 03, 2025
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
A Single Arm, Multicenter, Phase 2 Trial to Evaluate the Efficacy of Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Enrollment Status: Terminated
Publish Date: March 21, 2025
Intervention Type: Procedure, Drug
Study Drugs: Lenvatinib, Pembrolizumab
Study Phase: Phase 2
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer
Enrollment Status: Completed
Publish Date: December 10, 2024
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Cabazitaxel, Prednisone
Study Phase: Phase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study
177Lu Radiolabeled Monoclonal Antibody HuJ591-GS (177Lu-J591) in Patients With Nonprostate Metastatic Solid Tumors: A Pilot Study
Enrollment Status: Completed
Publish Date: February 02, 2022
Intervention Type: Drug
Study Drug: Lu-177 J591
Study Phase: Phase 1
View 7 Less Clinical Trials

72 Total Publications

A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.
Journal: European urology oncology
Published: February 16, 2025
Similar Doctors
Advanced in Sturge-Weber Syndrome
Dr. Yiwu J. Huang
Hematology Oncology | Hematology | Oncology
Advanced in Sturge-Weber Syndrome
Dr. Yiwu J. Huang
Hematology Oncology | Hematology | Oncology

Mmc Hematology Oncology Fpp

4802 10th Ave, 
Brooklyn, NY 
 (9.0 mi)
718-765-2600
Languages Spoken:
English
See accepted insurances

Yiwu Huang is a Hematologist Oncology specialist and a Hematologist in Brooklyn, New York. Dr. Huang and is rated as a Distinguished provider by MediFind in the treatment of Sturge-Weber Syndrome. His top areas of expertise are Stomach Cancer, Familial Colorectal Cancer, Colorectal Cancer, and Nasopharyngeal Carcinoma.

Experienced in Sturge-Weber Syndrome
Dr. Ashish Saxena
Hematology Oncology | Oncology | Hematology
Experienced in Sturge-Weber Syndrome
Dr. Ashish Saxena
Hematology Oncology | Oncology | Hematology

Weill Medical College Of Cornell

525 E 68th St, 
New York, NY 
 (0.1 mi)
212-746-2850
Languages Spoken:
English
Offers Telehealth

Ashish Saxena is a Hematologist Oncology specialist and an Oncologist in New York, New York. Dr. Saxena and is rated as a Distinguished provider by MediFind in the treatment of Sturge-Weber Syndrome. His top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Experienced in Sturge-Weber Syndrome
Dr. Anthony F. Provenzano
Hematology Oncology | Oncology | Hematology
Experienced in Sturge-Weber Syndrome
Dr. Anthony F. Provenzano
Hematology Oncology | Oncology | Hematology

Lawrence Medical Associates PC

55 Palmer Ave, 
Bronxville, NY 
 (13.7 mi)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Provenzano is a Hematologist Oncology specialist and an Oncologist in Bronxville, New York. Dr. Provenzano and is rated as an Advanced provider by MediFind in the treatment of Sturge-Weber Syndrome. His top areas of expertise are Pleuropulmonary Blastoma, Paget Disease of the Breast, Breast Cancer, and Wandering Spleen.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Molina's expertise for a condition
ConditionClose
View All 9 Distinguished Conditions
View All 26 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile